The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers
|
|
- Arlene Sparks
- 5 years ago
- Views:
Transcription
1 Br J Clin Pharmacol 1996; 41: The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers J. ROBERTS, D. G. WALLER, A. G. RENWICK, N. O SHEA, B. S. MACKLIN & M. BULLING Clinical Pharmacology Group, University of Southampton, Biomedical Sciences Building, Southampton, UK 1 The effects of benzhexol on the absorption and pharmacokinetics of an oral dose of levodopa have been studied in 1 young healthy volunteers. Subjects were given a suspension of levodopa (25 mg) 9 min after either benzhexol (5 mg) or placebo in a randomized cross over design with doses separated by at least 1 week; on each occasion carbidopa was given 1 h before and 5 h after the dose of levodopa. Soluble paracetamol and radiolabelled DTPA were given with the levodopa as markers of gastric emptying. 2 Most subjects showed two peaks in the levodopa plasma concentration time curve on the placebo day, with the second minor peak occurring 1 2 h after the dose. After benzhexol administration all subjects showed two or more peak levodopa concentrations in plasma. Benzhexol administration caused a significant decrease in the maximum concentration (43%; P<.5) of the initial peak and an increase ( 22%; P<.1) in the maximum concentration of the second peak. This change in absorption profile caused by benzhexol significantly altered the ratios of the second peak compared with the initial peak for both the maximum concentrations (P<.2) and for the AUC values (P<.5). Benzhexol administration did not affect the total AUC of levodopa (7.3±1.9 vs 7.19±1.26 mg ml 1h; means±s.d.). 3 The plasma concentration time curves for paracetamol showed similar profiles to those for levodopa and the ratios of the peak concentrations and AUC values for the second peak compared with the initial peak were increased significantly by benzhexol administration (P<.5). The total AUC of paracetamol was not affected by benzhexol administration (39.4±8.2 vs 4.±8.9 mgml 1h; mean±s.d.) 4 Benzhexol altered the gastric emptying profile, shown by c-scintigraphy, with a reduced extent of initial emptying prior to the establishment of the plateau which is characteristic of levodopa administration in the fasting state. In consequence the ratio of the second to the initial phase of emptying was significantly higher (P<.1) following benzhexol treatment. 5 Benzhexol reduces the initial phase of gastric emptying after a dose of levodopa so that there is a decrease in the initial peak and a greater proportion of the dose is absorbed subsequently following the second phase of gastric emptying which occurs approximately 1 h later. Theoretically, this altered concentration time profile could be an advantage for some patients with Parkinson s disease. Keywords levodopa benzhexol gastric-emptying pharmacokinetics drug absorption Correspondence: Dr A. G. Renwick, Clinical Pharmacology Group, University of Southampton, Biomedical Sciences Building, Bassett Crescent East, Southampton SO16 7PX, UK Blackwell Science Ltd 331
2 332 J. Roberts et al. Introduction 72.5 (range ) kg, were studied. All gave written informed consent and the study was approved by the The rate of absorption of levodopa after oral adminislocal ethics committee and the Administration of tration is determined principally by the rate of gastric Radioactive Substances Advisory Committee. Subjects emptying [1]. Little levodopa is absorbed from the attended on two occasions separated by at least 1 week. stomach, and most undergoes active transport from the Subjects fasted overnight since dietary amino acids can small intestine via a specific uptake mechanism for large reduce levodopa absorption [ 7]. neutral amino acids. An unusual feature of levodopa In random order they were given either benzhexol pharmacokinetics is the frequent presence of more than (5 mg; Artane, Lederle Laboratories) or ascorbic acid one peak in the plasma concentration time curve (25 mg; as a placebo tablet) 9 min before receiving following a single oral dose. In young healthy volunteers, levodopa. Carbidopa, the peripheral dopa decarboxylase the liquid component of gastric emptying usually shows inhibitor, was given orally 1h before (1 mg) and a monophasic profile when assessed by gamma camera 5 h after (5 mg) the dose of levodopa. Just prior to the scintigraphy. Following an oral dose of levodopa, the dose of levodopa, subjects were positioned semiinitial rapid emptying is interrupted by a plateau phase recumbent on their back under a gamma camera with negligible emptying, followed by a second phase of (Siemens LFOV with 14 kev parallel hole collimator). rapid emptying [ 1]. In association with this pattern, Soluble paracetamol (1 g) and 99m-DTPA (diethylenetriseparate peak concentrations of levodopa are produced aminepentaacetic acid; 12 MBq), as pharmacological after each rapid emptying phase. Levodopa alters the and scintographic markers of gastric emptying, and gastric emptying profile in both young [1] and elderly levodopa (25 mg as a suspension) were given orally in [ 2] volunteers. Multiple plasma peaks are detected 1 ml water. when a single dose of levodopa is given in the fasting Gamma camera images of the gastric region of interest state [1, 2] and following a low protein meal [3] but were acquired every 6 s and imaging was continued are less common following a high protein meal [3]. until all the isotope appeared to have left the stomach. Rapid fluctuations in the clinical response to levodopa Blood samples (1 ml) were drawn through an indwellbecome increasingly common in patients with advanced ing forearm cannula immediately before and at 15, 3, Parkinson s disease. In some of these patients the 45, 6, 75, 9, 15, 12, 18, 24, 3, 36, 42 and effectiveness of levodopa is consistent only in the 48 min after levodopa was given. Plasma was stored at presence of a steady plasma drug concentration and 2 C until analysis. Paracetamol and levodopa were delayed or erratic gastric emptying may be an important measured as described previously [ 1, 6]. determinant of fluctuations in clinical response in some patients with Parkinson s disease [4]. In this situation the neuronal storage capacity for dopamine is believed Data analysis to be markedly reduced so that minute to minute delivery of levodopa may determine the extent to which Multiple peaks occur commonly in the plasma concensymptoms are relieved. The erratic and fluctuating tration time curve for levodopa following oral adminisplasma concentrations of levodopa produced by intertration. The concentration of the initial plasma peak of mittent delays in gastric emptying could therefore be levodopa or paracetamol (C ), the concentration of the detrimental. Fluctuations may be greatest with the first 1 second peak (C ) and the times of C and C (t and t ) dose of the day which is usually taken on an empty 2 are the observed values. The area under the plasma stomach. drug concentration-time curve (AUC) was calculated Anticholinergic drugs, such as benzhexol, are used in using the linear trapezoidal rule with extrapolation to the management of Parkinson s disease, often in combiinfinity; the terminal half-life was calculated by least nation with levodopa. The muscarinic receptor blockade squares regression analysis and the mean residence time produced by this class of drug is also believed to be from the AUC and the area under the first moment of responsible for their ability to inhibit gastric motility the plasma drug concentration-time curve (AUMC) as [ 5, 6]. The consequent delay in gastric emptying could described by Gibaldi & Perrier [8]. The paracetamol theoretically further affect the absorption of levodopa. and levodopa assays had coefficients of variations of The present study investigated the effect of approximately 5%. In the analysis of the plasma co-administration of the anticholinergic drug, benzhexol, concentration time curves for paracetamol and levoon the pattern of gastric emptying and absorption of dopa, a peak in the profile was defined as a rise in levodopa in healthy volunteers in order to define the concentration of at least 5% if it occurred in both extent of any drug interaction in the absence of ageing levodopa and paracetamol curves, or 1% if it was only and/or pathological changes likely to be present in present in one. patients with Parkinson s disease. The ratios of the peak concentrations for the second peak/first peak (C /C ) were calculated from the measured values. The ratios of the AUC values for the second peak/first peak were calculated by measuring Methods the AUC of the first peak as the (AUC + zero-trough Ten healthy male volunteers, with a mean age of 21 C /terminal slope) and the AUC of the second peak trough (range 2 22) years and with a mean body weight of was the (AUC AUC ). zero-infinity first peak
3 Benzhexol and levodopa absorption 333 Full details of the method of analysis of the scinti- levodopa (Figure 1) showed significantly lower concentrations graphic gastric emptying curves have been given elsewhere at early time points on the benzhexol day. The [1]. A plateau in the gastric emptying curve was curves crossed over at about h and significantly defined as a period with no gastric emptying for at least higher concentrations were detected at later time points 15 min. Measurements obtained from the curves were on the benzhexol day. the half-lives of the initial and final phases of emptying, The initial peak plasma levodopa concentration (C ) 1 the mean residence time for gastric contents (calculated was significantly reduced after benzhexol by a mean of from the AUC and AUMC of gastric radioactivity from 43% (P<.2) while the second peak (C ) although 2 the scintiscan) and the ratio of the decrease in gastric 22% higher after benzhexol was not significantly radioactivity in phase 2 compared with phase 1 (where different (Table 1). However, there was a significant three phases of emptying were recorded, the last two increase in the ratio of C /C (P<.2) and the ratio of were combined in this measure). the areas under the concentration-time curves for the The gastric emptying profiles were incomplete for two two peaks (AUC peak 2/AUC peak 1) (P<.5). The subjects who vomited about 1 2 min after the establishsment of a plateau phase of gastric emptying on the benzhexol but that to the second peak (t ) was 2 time to the first peak (t ) was increased slightly with 1 placebo day; in both cases the majority of gastric unchanged (Table 1). emptying occurred in the initial phase since the ratios There was no significant treatment related difference phase 2/phase 1 were.25 and.16. In consequence in the total AUC extrapolated to infinity despite the only the initial emptying half-life, and the ratio of phase greater proportion of the dose retained in the stomach 2/phase 1 emptying could be calculated from these data. Blood samples were collected normally for these subjects and the data are presented and discussed for treatment 6. related differences using data for all 1 subjects and also separately excluding (as appropriate) the data for the two subjects who vomited. Correlations were derived from linear least squares 5. analysis, and statistical comparisons performed using Student s t-test for paired data or the Mann Whitney U/Wilcoxon signed rank test; a P value of <.5 was taken as statistically significant. Results are expressed 4. as the mean±s.d. in the table and text and means±s.e.mean in figures. Results L evodopa pharmacokinetics On the placebo day seven subjects showed two peaks in the levodopa plasma concentration time curve; of the three subjects with a single levodopa peak, one 1. showed monophasic gastric emptying, one vomited and one showed a single levodopa peak despite a plateau on the gamma camera data (with about 25% retained) and a clear second peak of paracetamol coinciding with the end of the plateau. After benzhexol, nine Time (h) subjects had two peaks in the plasma levodopa concentration time curve and the other had three. The subject Figure 1 Plasma levodopa concentration-time curves for with three levodopa peaks also had three peaks of subjects given a suspension of levodopa with soluble paracetamol and two plateaux on the gamma scan. paracetamol and Tc-DTPA after pretreatment with Another subject with two plateaux on the gamma scan carbidopa and either placebo (solid circles) or benzhexol reached the end of the second plateau at a time when (open circles). The data are the mean values for 1 subjects blood sampling may have been too infrequent to detect with s.e.mean shown by bar lines. Statistically significant a third plasma drug peak so that only two peaks of treatment related differences (P<.5) were found by paired t-test at.25,.5,.75, 1, 4, 6 and 7 h and by signed rank test both levodopa and paracetamol were found. On the at.25,.5,.75, 1, 3, 4, 6 and 7 h. [Exclusion of the postbenzhexol day one subject showed a small secondary emesis data for the two subjects who vomited after 3 min (and possibly artefactual) increase (1%) in levodopa at and 5 min on the placebo day did not appreciably alter any a single time point which did not correspond to a of the mean concentrations (<8 ng/ml 1 difference); plateau on the gamma camera scan or a second peak in statistically significant differences (P<.5) were found by the paracetamol data. paired t-test at.25,.5,.7 and 1 h and by signed rank test The mean plasma concentration-time curves for at.25,.5,.7, 1, 1.5, 3, 4, 5, 6, 7 and 8 h]. Concentration (µg ml 1 ) 3. 2.
4 334 J. Roberts et al. Table 1 The effect of benzhexol on the absorption of levodopa and paracetamol when co-administered with Tc-DTPA L evodopa Paracetamol Placebo Benzhexol Mean of differences Placebo Benzhexol Mean of differences (95% CI ) (95% CI ) Number of subjects with two or more peaks C (mgml 1) ± ±2.29** 2.42 ( ) 17.4± ± ( ) t (min) 1 23 (15 3) 3 (15 3) 3 ( 5 +11) 15 (15 19) 23 (15 3) 8 ( +15) C (mgml 1) 2 2.2± ± ( ) 7.9± ± ( ) t (min) 2 9 (9 15)7 15 (9 19) 2 ( ) 9 (9 15)7 15 (9 15)9 15 ( ) Time to trough (min) 77±167 71±12 11 ( ) 75±157 63± ( 31 +1) AUC (mg ml 1h) 7.3± ± ( ) 39.4±.2 4.± ( ) Ratios C /C.63± ±1.24** 1.32 ( ).64± ±.85* 1.8 ( ) AUC /AUC.25± ±1.49* 1.51 (.1 3.1).3± ±1.18* 1.53 ( ) The results are the means±s.d., except for t and t which are given as the median and interquartile range, for subjects given levodopa, paracetamol and Tc-DTPA following the administration 1 2 of placebo or benzhexol. The results are for 1 subjects except where indicated by a superscript (see text for details). *P<.5, **P<.2 by signed rank test. C concentration of initial peak 1 C concentration of second peak 2 t time of C 1 1 t time of C 2 2 AUC area under the concentration-time curve extrapolated to infinity AUC /AUC ratio of AUC of second peak/auc of initial peak (see text)
5 on the benzhexol day. However, any difference may have been minimized because two subjects vomited on the placebo day. Exclusion of the data for these subjects gave levodopa AUC values of 7.51±.89 mg ml 1h on the placebo day and 7.17±1.3 mg ml 1 h on the benzhexol day; the slight difference was not statistically significant by either paired t-test or signed rank test. The plasma levodopa profiles correlated closely with the pattern of gastric emptying as determined by both the gamma camera data and the plasma paracetamol data. Paracetamol pharmacokinetics Concentration (µg ml 1 ) Benzhexol and levodopa absorption 335 After placebo, most of the plasma paracetamol concentration time curves showed profiles consistent with the 8 levodopa profile or the pattern of gastric emptying (see below). One subject had a single paracetamol peak 6 despite showing a plateau on the gastric scan and two levodopa peaks, but the second phase of gastric emptying represented only 15% of the total: a single paracetamol 4 peak was also found in one of the two subjects who vomited. One subject showed a second minor paracetamol 2 peak (8% increase) which coincided with a 17% increase in levodopa concentration despite an apparently single phase of gastric emptying by scintigraphy. After benzhexol pretreatment only one subject showed Time (h) an apparent discrepancy since secondary peaks of both Figure 2 Plasma paracetamol concentration-time curves for paracetamol and levodopa were detected while the subjects given soluble paracetamol with levodopa and gastric emptying profile showed a slow emptying over Tc-DTPA after pretreatment with carbidopa and either about 2 h, but without a clear plateau phase. placebo (solid circle) or benzhexol (open circles). The data The difference between treatments in the levodopa are the mean values for 1 subjects with s.e.mean shown by profiles (Figure 1) was reflected in the corresponding bar lines. Statistically significant treatment related differences mean plasma paracetamol concentration time curves (P<.5) were found by paired t-test at.5,.75, 1, 3, 4, 7 (Figure 2). The plasma paracetamol concentrations and 8 h and by signed rank test at.25,.5,.75, 1, 3, 4, 5, 6, (Figure 2) on the benzhexol day were significantly lower 7 and 8 h. [Exclusion of the post-emesis data for the two subjects who vomited after 3 and 5 min on the placebo up to 1 h, which corresponded to the initial period of day did not appreciably alter any of the mean concentrations gastric emptying. The mean concentration time curves (<.2 mg ml 1difference); statistically significant differences crossed over between 1.5 and 1.75 h after dosing and (P<.5) were found by paired t-test at.5,.75, 1 and 3 h were significantly higher on the benzhexol day at later and by signed rank test at.25,.5,.75, 1, 3, 4, 5, 6, 7, 8 h]. time points. The initial peak plasma concentration of paracetamol was lower after benzhexol pretreatment while the second had two distinct emptying phases separated by a peak was higher (Table 1) although, unlike for levodopa, plateau. After pre-treatment with benzhexol, one subject these differences did not reach statistical significance. who demonstrated a plateau after placebo had a rapid Consequences of this shift in absorption profile were monophasic emptying pattern; another subject had a that the ratios of C /C and AUC peak 2/AUC peak 1 prolonged slow initial emptying phase lasting 2 h, were significantly higher after benzhexol pretreatment followed by a late rapid emptying but no clear plateau; (P<.5) (Table 1). The time to the trough paracetamol of the other eight, six showed a single plateau while two concentration was slightly less on the benzhexol day had three phases of rapid emptying separated by two (Table 1) possibly in part due to the reduced amount plateaux. being absorbed in the first hour following the dose The gastric radioactivity (Figure 3) showed a similar (Figures 2 and 3). mean profile on each study day with a plateau between The differences in absorption profiles did not result about 2 3 min and 7 8 min after dosing. There was in any treatment related difference in AUC of paraceta- a smaller decrease prior to the plateau on the benzhexol mol calculated to infinity. day and in consequence, the gastric radioactivity was significantly higher between 15 and 5 min on the benzhexol day. Gastric emptying There were no significant differences between placebo On the placebo study day, two subjects had a rapid monophasic gastric emptying pattern, the other eight and benzhexol days in the initial emptying half-life (8±5 vs 26±36 min), the time to the end of the first plateau (77±1 vs 74±12 min), the final emptying
6 336 J. Roberts et al. % initial activity peaks (r=.7; P<.1) and the time of the second peak (t 2 )(r=.766; P<.5). Gastric emptying and paracetamol The ratio of the proportion of gastric emptying in phase 2/phase 1 correlated with the ratios for paracetamol of C /C 2 (r=.921; P<.1) and AUC peak2/auc peak 1 (r=.978; P<.1). The time to the end of the plateau on the scan correlated with the time to trough paracetamol concentration (r=.697; P<.1) and t 2 for paracetamol (r=.825; P<.5). Paracetamol and levodopa Correlations were found between various paracetamol and levodopa pharmacokinetic indices, ie t (r=o.765; P<.2), t (r=.769; 1 2 P<.1), time to trough plasma concentrations (r=.853; P<.1), C /C (r=.963; P<.1) and AUC peak2/auc peak1 (r=.985 P<.1) Time (h) Discussion Figure 3 Gastric emptying profile determined by gamma- camera imaging for subjects given radiolabelled Tc-DTPA with levodopa, carbidopa and paracetamol after pretreatment with placebo (solid circles) or benzhexol (open circles). The data are the means with s.e.mean shown by bar lines for 1 subjects of the percent of the initial radioactivity remaining in the stomach up to 2 h after dosing. There were statistically significant treatment related differences (P<.5) by paired t- test at 15 5 min and by signed rank test at min and 8, 95 and 1 min. Data collected on the two subjects who vomited on the placebo day are included to the last time point measured (3 and 1 min) There was a high incidence of multiple plasma levodopa peaks in this study. We have previously reported a lower number in young healthy volunteers [ 1] after 125 mg levodopa given with carbidopa, although the incidence was greater in elderly subjects [2]. Since the elderly achieve higher plasma levodopa concentrations than the young, the concentration of levodopa or one of its metabolites in the blood may be directly related to the production of gastric stasis. The greater incidence of multiple peaks in the young volunteers in the present study (in the absence of benzhexol ) may have been due to the higher dose of levodopa. The current study confirms the central role of gastric emptying in determining the peripheral pharmaco- kinetics of levodopa. This study also provides further support for the value of paracetamol as a marker of gastric emptying [6]. Correlations between indices derived from paracetamol plasma concentrations and levodopa pharmacokinetics provided similar infor- mation to that obtained from scintigraphy. There was a close relationship between parameters derived from half-life (12±9 vs 6±6 min) or the mean residence time of gastric contents (31±16 vs 41±19 min). However, the ratio of the proportion of gastric emptying in phase 2 compared with that in phase 1 was significantly plasma paracetamol concentrations and those from the greater after benzhexol (1.12±1.1) compared with scan, despite a loss of precision due to less frequent placebo (.26±.37) (P<.1 by signed rank test) data sampling with paracetamol. indicating a lower extent of gastric emptying prior to Benzhexol administration altered the pattern of gastric the plateau on the benzhexol day (mean of difference emptying produced by levodopa since it significantly (95% CI);.86 ( )). shortened the duration of the initial rapid emptying phase, leading to gastric stasis after less gastric emptying and therefore, at much lower plasma levodopa concentrations. As a result, the overall absorption of levodopa Correlations between gastric emptying, levodopa and paracetamol Gastric emptying and levodopa Close correlations were found between the proportion of gastric emptying in phase 2/phase 1 and the ratios for levodopa of peak concentrations C /C (r=.921; P<.1) and AUC peak 2/AUC peak 1 (r=.978; P<.1). The time to the end of the plateau on the scan correlated with both time to trough plasma levodopa concentration between was significantly slower and the initial peak plasma concentration was reduced, although the relative bioavailability of levodopa was unchanged. This could have important clinical consequences in those patients with Parkinson s disease who rely on high plasma levodopa concentrations to maintain a clinical response. Although the initial absorption of levodopa was reduced, the fluctuations in the plasma concentrations were smaller after benzhexol and this may be advantageous
7 Benzhexol and levodopa absorption 337 for patients who suffer from the on-off phenomenon emptying in healthy elderly volunteers. Eur J Clin Pharmacol in whom large variations in delivery of levodopa to 1992; 42: striatal neurons contributes to their disability. A small 3 Robertson DRC, Higginson I, Macklin BS, Renwick AG, study in six patients treated chronically with levodopa Waller DG, George, CF. The influence of protein containing meals on the pharmacokinetics of levodopa in healthy plus benserazide and the anticholinergic drug orphenadvolunteers. Br J Clin Pharmacol 1991; 31: rine, found delayed levodopa absorption in one and 4 Deleu D, Ebinger G, Michotte Y. Clinical and pharmacodecreased absorption in two patients; the authors kinetic comparison of oral and duodenal delivery of concluded that the chronic use of an anticholinergic levodopa/carbidopa in patients with Parkinson s disease agent may produce to a less predictable pattern of with a fluctuating response to levodopa. Eur J Clin levodopa absorption [9]. The data reported in healthy Pharmacol 1991; 41: young subjects in the present paper demonstrate a 5 Jaup BH, Stockbrugger RW, Dotevall G. Comparison clear but predictable effect of benzhexol on levodopa between the effects of pirenzepine and L-hyoscyamine in absorption. man. Scand J Gastroenterol 1982; 17: We conclude from this study that the addition of 6 Rashid MU, Bateman DN. Effect of intravenous atropine anticholinergic drugs to the therapy of patients with on gastric emptying, paracetamol absorption and heart rate in young and fit elderly volunteers. Br J Clin Pharmacol Parkinson s disease with levodopa could affect the 199; 3: profile of plasma levodopa concentrations. The change 7 Lennernas H, Nilsson D, Aquilonius SM, Akrenstedt O, in plasma profile is most likely to be of clinical relevance Knutson L, Paalzow K. The effect of L-leucine on the in patients who have advanced disease, particularly if absorption of levodopa, studied by regional jejunal perfusion they already show a fluctuating response to treatment. in man. Br J Clin Pharmacol 1993; 35: Gibaldi M, Perrier D. In Pharmacokinetics, New York: Marcel Dekker, References 9 Cortin M, Riva R, Martinelli P, Procaccianti G, Albani F, Baruzzi A. Combined levodopa-anticholinergic therapy in 1 Robertson DRC, Renwick AG, Wood ND, et al. The the treatment of Parkinson s disease. Clin Neuropharmacol influence of levodopa on gastric emptying in man. Br J Clin 1991; 14: Pharmacol 199; 29: Robertson DRC, Renwick AG, Macklin B, Jones S, Waller (Received 2 July 1995, DG, George CF. The influence of levodopa on gastric accepted 2 December 1995)
Flecainide pharmacokinetics in healthy volunteers: the influence of urinary ph
Br. J. clin. Pharmac. (1985), 20, 333-338 Flecainide pharmacokinetics in healthy volunteers: the influence of urinary ph A. JOHNSTON, S. WARRNGTON' & P. TURNER Department of Clinical Pharmacology, St Bartholomew's
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationThe dependence of paracetamol absorption on the rate of gastric emptying
Br. J. Pharmac. (1973), 47, 415-421. The dependence of paracetamol absorption on the rate of gastric emptying R.. HADING, J. NIMMO, L F. PRSOTT AND P. TOTHILL University Departments of Therapeutics and
More informationPreliminary studies of the pharmacokinetics and pharmacodynamics
Br. J. clin. Pharmac. (1987), 23, 137-142 Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers WENDY B. TAYLOR & D. N. BATEMAN Wolfson Unit of Clinical
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationBioavailability and Related Pharmacokinetics in Man of Orally Administered L-5-Hydroxytryptophan in Steady State
Acra pharmacol. et roxicol. 1980, 46, 257-262. From the University Department of Neurology, the Research Laboratory for etabolic Disorders of the University Department of Clinical Chemistry, Aarhus Kornrnunehospital,
More informationNoncompartmental Analysis (NCA) in PK, PK-based Design
Noncompartmental Analysis (NCA) in PK, PK-based Design Helmut Schütz BEBAC Consultancy Services for Bioequivalence and Bioavailability Studies 17 Vienna, Austria helmut.schuetz@bebac.at Bioequivalence
More informationBiopharmaceutics Lecture-11 & 12. Pharmacokinetics of oral absorption
Biopharmaceutics Lecture-11 & 12 Pharmacokinetics of oral absorption The systemic drug absorption from the gastrointestinal (GI) tract or from any other extravascular site is dependent on 1. 2. 3. In the
More informationNIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2010 September 22.
NIH Public Access Author Manuscript Published in final edited form as: Transplant Proc. 1990 February ; 22(1): 57 59. Effect of Hepatic Dysfunction and T Tube Clamping on FK 506 Pharmacokinetics and Trough
More informationDistribution of a liquid meal within the stomach and
Gut, 1982, 23, 683-691 Distribution of a liquid meal within the stomach and gastric emptying after vagotomy and drainage operations O LAWAETZ,* Y ARITAS, N J G BROWN, D N L RALPHS, and E SJ0NTOFT* From
More informationAustin Radiological Association Nuclear Medicine Procedure GASTRIC EMPTYING STUDY (Tc-99m-Sulfur Colloid in Egg)
Austin Radiological Association Nuclear Medicine Procedure GASTRIC EMPTYING STUDY (Tc-99m-Sulfur Colloid in Egg) Overview Indications The Gastric Emptying Study demonstrates the movement of an ingested
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationPharmacokinetics of ibuprofen in man. I. Free and total
Pharmacokinetics of ibuprofen in man. I. Free and total area/dose relationships Ibuprofen kinetics were studied in 15 subjects after four oral doses. Plasma levels of both total and free ibuprofen were
More informationDisposition of metronidazole and its effects on sulphasalazine
Br. J. clin. Pharmac. (1986), 21, 431-435 Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease J. L. SHAFFER*,' A. KERSHAW2 & J. B. HOUSTON2
More informationThe pharmacokinetics and dose proportionality of cilazapril
Br. J. clin. Pharmac. (1989), 27, 199S-204S The pharmacokinetics and dose proportionality of cilazapril J. MASSARELLA, T. DEFEO, A. LIN, R. LIMJUCO & A. BROWN Departments of Drug Metabolism and Clinical
More informationAnticholinergic withdrawal and benzhexol treatment
Journal of Neurology, Neurosurgery, and Psychiatry, 1973, 36, 936-941 Anticholinergic withdrawal and benzhexol treatment in Parkion's disease P. M. HORROCKS, D. J. VICARY, J. E. REES, J. D. PARKES, AND
More informationClinical Trials A Practical Guide to Design, Analysis, and Reporting
Clinical Trials A Practical Guide to Design, Analysis, and Reporting Duolao Wang, PhD Ameet Bakhai, MBBS, MRCP Statistician Cardiologist Clinical Trials A Practical Guide to Design, Analysis, and Reporting
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationEffect of Septilin A Herbal Preparation on Pharmacokinetics of Carbamazepine in Rabbits
[Indian Journal of Physiology and Pharmacology (1998): (42), 4, 527] Effect of Septilin A Herbal Preparation on Pharmacokinetics of Carbamazepine in Rabbits Garg, S.K., Afm. S. Islam and Naresh Kumar Department
More informationPHARMACOKINETICS OF DRUG ABSORPTION
Print Close Window Note: Large images and tables on this page may necessitate printing in landscape mode. Applied Biopharmaceutics & Pharmacokinetics > Chapter 7. Pharmacokinetics of Oral Absorption >
More informationGastrointestinal Transit and Drug Absorption
February 2002 Biol. Pharm. Bull. 25(2) 149 164 (2002) 149 Review Gastrointestinal Transit and Drug Absorption Toshikiro KIMURA* and Kazutaka HIGAKI Faculty of Pharmaceutical Sciences, Okayama University,
More informationLippincott Questions Pharmacology
Lippincott Questions Pharmacology Edition Two: Chapter One: 1.Which one of the following statements is CORRECT? A. Weak bases are absorbed efficiently across the epithelial cells of the stomach. B. Coadministration
More informationDrugs used in Parkinsonism
Drugs used in Parkinsonism قادة فريق علم األدوية : لي التميمي & عبدالرحمن ذكري الشكر موصول ألعضاء الفريق املتميزين : جومانة القحطاني ندى الصومالي روان سعد القحطاني pharma436@outlook.com @pharma436 Your
More informationPlasma Paracetamol Concentrations Measured by Fluorescence Polarization Immunoassay and Gastric Emptying Time
Tohoku J. exp. Med., 1988, 155, 159-164 Plasma Paracetamol Concentrations Measured by Fluorescence Polarization Immunoassay and Gastric Emptying Time FUMIAKI KOIZUMI, TAKESHI KAWAMURA, AKIRA ISHIMORI,
More informationJohnson & Johnson Pharmaceutical Research & Development, L.L.C.
SYNOPSIS Issue Date: 27 April 2009 Document No.: EDMS-PSDB-9908562:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient Johnson & Johnson Pharmaceutical Research & Development,
More informationOsnove farmakokinetike. Aleš Mrhar. Prirejeno po. A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne,
Osnove farmakokinetike Aleš Mrhar Prirejeno po A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne, College of Pharmacy, University of Oklahoma Pharmacokinetics/Pharmacodynamics Pharmacodynamics
More informationStudy Centers: This study was conducted in 2 centers in Italy.
Title of Trial: A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson
More informationPublic Assessment Report. Scientific discussion. Ropinirol Actavis. Ropinirole hydrochloride DK/H/1212/ /DC
Public Assessment Report Scientific discussion Ropinirol Actavis Ropinirole hydrochloride DK/H/1212/001-007/DC This module reflects the scientific discussion for the approval of Ropinirole film-coated
More informationDOMPERIDONE BNF 4.6. Domperidone is a dopamine type 2-receptor antagonist. It is structurally related to the
DOMPERIDONE BNF 4.6 Class: Prokinetic anti-emetic. Indications: Nausea and vomiting, dysmotility dyspepsia, gastro-oesophageal reflux. Pharmacology Domperidone is a dopamine type 2-receptor antagonist.
More informationLack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids
Blackwell Science, Ltdxford, UKBJCPBritish Journal of Clinical Pharmacology0306-5251Blackwell Science, 200254riginal Articleseltamivir and antacids lack of kinetic interactionp. Snell et al. Lack of pharmacokinetic
More informationThe excretion of zopiclone into breast milk
Br. J. clin. Pharmac. (1990), 30, 267-271 The excretion of zopiclone into breast milk I. MATHESON1, H. A. SANDE2 & J. GAILLOT3 'Department of Pharmacotherapeutics, University of Oslo, Oslo, 2Department
More informationReview article: pharmacology of esomeprazole and comparisons with omeprazole
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 5 9. Review article: pharmacology of esomeprazole and comparisons with omeprazole J. DENT Department of Gastroenterology, Hepatology and General Medicine, Royal
More informationEntacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose
Blackwell Science, LtdOxford, UKBJCPBritish Journal of Clinical Pharmacology36-525Blackwell Science, 2254Original ArticleEntacapone increases concentrations of L-dopaH. Heikkinen et al. Entacapone improves
More informationAustin Radiological Association Nuclear Medicine Procedure SPHINCTER OF ODDI STUDY (Tc-99m-Mebrofenin)
Austin Radiological Association Nuclear Medicine Procedure SPHINCTER OF ODDI STUDY (Tc-99m-Mebrofenin) Overview Indications The successively demonstrates hepatic perfusion, hepatocyte clearance, hepatic
More informationContinuous dopaminergic stimulation in a patient treated with daytime Levodopa-carbidopa intestinal gel and overnight Rotigotine: a case report
Acta Biomed 2017; Vol. 88, N. 2: 190-195 DOI: 10.23750/abm.v88i2.5038 Mattioli 1885 Case report Continuous dopaminergic stimulation in a patient treated with daytime Levodopa-carbidopa intestinal gel and
More informationEffect of Histamine H2-receptor Antagonists on. Acetaminophen and its Metabolites in Human Plasma
Jpn. J. Pharm. Health Care Sci. Effect of Histamine H2-receptor Antagonists on Acetaminophen and its Metabolites in Human Plasma Hiroki Itoh* and Masaharu Takeyama Department of Clinical Pharmacy, Oita
More informationUsing Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop
Using Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop Topics to be Addressed Why AMS? AMS for mass balance studies with vismodegib AMS for absolute bioavailability
More informationSection 3.F and Section 6 Human Pharmacokinetics and Bioavailability
ZITHROMAX AZITHROMCYIN MYCOBACTERIUM AVIUM INTRACELLULARE TREATMENT NDA SUPPLEMENT Section 3.F and Section 6 Human Pharmacokinetics and Bioavailability Clinical Pharmacology Cross Reference from 3.H.1
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen This full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/14779
More informationTCP Transl Clin Pharmacol
TCP 2015;23(1):26-30 http://dx.doi.org/10.12793/tcp.2015.23.1.26 Bioequivalence study of Donepezil hydrochloride in healthy Korean volunteers ORIGINAL ARTICLE Yewon Choi 1, Su-jin Rhee 1, In-Jin Jang 1,
More informationEffect of intravenous atropine on gastric emptying, paracetamol absorption, salivary flow and heart rate in young and fit elderly volunteers
Br. J. clin. Pharmac. (1990), 30, 25-34 Effect of intravenous atropine on gastric emptying, paracetamol absorption, salivary flow and heart rate in young and fit elderly volunteers M. U. RASHID & D. N.
More informationBasic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations
Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations Rosenbaum, Sara E. ISBN-13: 9780470569061 Table of Contents 1 Introduction to Pharmacokinetics and Pharmacodynamics.
More informationBORDEAUX MDS WINTER SCHOOL FOR YOUNG
BORDEAUX MDS WINTER SCHOOL FOR YOUNG NEUROLOGISTS INFUSION THERAPIES IN PARKINSON S DISEASE Apomorphine, T. Henriksen Tove Henriksen, MD MDS Clinic University Hospital of Bispebjerg, Copenhagen MOTOR FLUCTUATIONS
More informationPHAR 7633 Chapter 20 Non Compartmental Analysis
Student Objectives for this Chapter PHAR 7633 Chapter 20 Non Compartmental Analysis To understand and use the non compartmental approach to parameter estimation be able to define, use, and calculate the
More information1. BACKGROUND. Lovastatin β-hydroxyacid No effect on methane production Inhibits cholesterol synthesis
1. BACKGRUND Methane production by the archeon Methanobrevibacter smithii (M. smithii) is a ubiquitous process in the intestine, disposing of hydrogen and other by-products formed during carbohydrate digestion
More informationPK-UK Challenges and benefits of using PBPK to evaluate an IVIVC for drugs with nonideal solubility and/or permeability. Bath, November 2014
PK-UK 2014 Challenges and benefits of using PBPK to evaluate an IVIVC for drugs with nonideal solubility and/or permeability Bath, November 2014 Prof. Dr. Jennifer Dressman Dressman Bath 2014 Why IVIVC
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More information1. Gastric Emptying Time Anatomically, a swallowed drug rapidly reaches the stomach. Eventually, the stomach empties its content in the small
Lecture-5 1. Gastric Emptying Time Anatomically, a swallowed drug rapidly reaches the stomach. Eventually, the stomach empties its content in the small intestine. Because the duodenum has the greatest
More informationa very short half-life, but its main metabolite, which
Br. J. clin. Pharmac. (1979), 8, 3IS-35S BIOAVAILABILITY OF TMAZPAM IN SOFT GLATIN CAPSULS L.M. FUCCLLA Department of Clinical Pharmacology, Carlo rba Research Institute, Milan, Italy 1 Healthy volunteers
More informationPHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 4120 Second Exam Key Fall 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /10 ponts 2. /20 points 3. /10 points 4. /10 points
More informationSaliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion Classification System
Drugs R D (2015) 15:79 83 DOI 10.1007/s40268-015-0080-1 ORIGINAL RESEARCH ARTICLE Saliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion
More informationNontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment
Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment Please consider the following questions. If you do not feel confident about the material being covered, then it is recommended
More informationUnderstand the physiological determinants of extent and rate of absorption
Absorption and Half-Life Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand Objectives Understand the physiological determinants of extent and rate of absorption
More information1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?
Page 1 PHAR 750: Biopharmaceutics/Pharmacokinetics October 23, 2009 - Form 1 Name: Total 100 points Please choose the BEST answer of those provided. For numerical answers, choose none of the above if your
More informationResults. Subject Disposition and Demographics Of 37 enrolled subjects, 23 (62.2%) completed the study
Poster 5-20 Effect of Gastric ph on the Bioavailability of in Healthy Subjects James Longstreth, PhD, Marijke H. Adams, PharmD, PhD, 2 Vasi Sperry, PhD, 3 Dan Kajdasz, PhD, 3 Carol R. Reed, MD 3 Longstreth
More informationTreatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS
Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS
More informationWHY... 8/21/2013 LEARNING OUTCOMES PHARMACOKINETICS I. A Absorption. D Distribution DEFINITION ADME AND THERAPEUIC ACTION
PHARMACOKINETICS I Absorption & Distribution LEARNING OUTCOMES By the end of the lecture students will be able to.. Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/08/21) Define pharmacokinetics,
More informationAltered GI absorption in special populations: An industry perspective
Altered GI absorption in special populations: An industry perspective Cordula Stillhart and Neil J. Parrott F. Hoffmann La Roche Ltd, Basel (CH) UNGAP WG meeting, Leuven (B) 8 March 2018 Current challenges
More informationBetween-subject and within-subject variations in the
Br J clin Pharmac 1994; 37: 427-431 Between-subject and within-subject variations in the pharmacokinetics of ethanol A. W. JONES' & K. A. JONSSON2 'Departments of Alcohol Toxicology and 2Internal Medicine,
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2011 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /200 pts 1 Question Set I (True or
More informationIn vitro and in vivo deconvolution assessment of drug release kinetics from oxprenolol Oros preparations
Br. J. clin. Pharmac. (1985), 19, 151S-162S In vitro and in vivo deconvolution assessment of drug release kinetics from oxprenolol Oros preparations F. LANGENBUCHER & J. MYSICKA Pharmaceutical Development,
More informationThe pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in.
Br. J. clin. Pharmac. (1987), 24, 493-501 The pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in human volunteers and patients with reversible
More informationPharmacokinetics in the critically ill. Intensive Care Training Program Radboud University Medical Centre Nijmegen
Pharmacokinetics in the critically ill Intensive Care Training Program Radboud University Medical Centre Nijmegen In general... Critically ill patients are at higher risk for ADE s and more severe ADE
More informationThe effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics
Br. J. clin. Pharmac. (1984), 18, 393-400 The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics T. K. DANESHMEND* & C. J. C. ROBERTS University Department of Medicine, Bristol
More informationBIOPHARMACEUTICS and CLINICAL PHARMACY
11 years papers covered BIOPHARMACEUTICS and CLINICAL PHARMACY IV B.Pharm II Semester, Andhra University Topics: Absorption Distribution Protein binding Metabolism Excretion Bioavailability Drug Interactions
More informationBORDEAUX MDS WINTER SCHOOL FOR YOUNG
BORDEAUX MDS WINTER SCHOOL FOR YOUNG NEUROLOGISTS HOW TO EVALUATE MOTOR COMPLICATIONS IN PARKINSON'S DISEASE T. Henriksen Tove Henriksen, MD MDS Clinic University Hospital of Bispebjerg, Copenhagen MOTOR
More informationAbsence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin
Blackwell Science, LtdOxford, UKBJCPBritish Journal of Clinical Pharmacology0306-5251Blackwell Science, 200254Original ArticleFondaparinux warfarin interactionr. A. Faaij et al. Absence of an interaction
More informationLisinopril and nifedipine: No acute interaction in normotensives
Br. J. clin. Pharmac. (1988), 25, 307-313 Lisinopril and nifedipine: No acute interaction in normotensives K. R. LEES & J. L. REID University Department of Materia Medica, Stobhill General Hospital, Glasgow
More informationIntroduction. The oxytocin/ / vasopressin receptor antagonist, atosiban, delays the gastric emptying of a semisolid meal compared to saline in human
The oxytocin/ / vasopressin receptor antagonist, atosiban, delays the gastric emptying of a semisolid meal compared to saline in human Bodil Ohlsson, et. al., Sweden BMC Gastroenterology, 2006 Presented
More informationVolume 1(3) May-June 2013 Page 351
ISSN: 2321-5674(Print) BIOAVAILABILITY: CRITERIA FOR APPROVING A DRUG PRODUCT FOR MARKETING Sandhya Singh 1, Faheem Ajmal Ansari 1, Shravan Paswan 2*, Rnjan Kumar Sharma 2, Alok Ranjan Gaur 3 1 Azad Institute
More informationDefine the terms biopharmaceutics and bioavailability.
Pharmaceutics Reading Notes Define the terms biopharmaceutics and bioavailability. Biopharmaceutics: the area of study concerning the relationship between the physical, chemical, and biological sciences
More informationClinical pharmacokinetics of meropenem after the first and tenth intramuscular administration
Journal of Antimicrobial Chemotherapy (1996) 37, 775-781 Clinical pharmacokinetics of meropenem after the first and tenth intramuscular administration A. Novelli', T. Mazzei', E. Meli*, S. Conti', S. Fallani'
More informationPharmacokinetics Overview
Pharmacokinetics Overview Disclaimer: This handout and the associated lectures are intended as a very superficial overview of pharmacokinetics. Summary of Important Terms and Concepts - Absorption, peak
More informationEuropean public MRL assessment report (EPMAR)
15 November 2016 EMA/CVMP/351687/2016 Committee for Medicinal Products for Veterinary Use European public MRL assessment report (EPMAR) (bovine species) On 17 October 2016 the European Commission adopted
More informationA Bioequivalence Study of an Albendazole Oral Suspension Produced in Iran and a Reference Product in Sheep
A Bioequivalence Study of an Albendazole Oral Suspension Produced in Iran and a Reference Product in Sheep Ali Eslami, DVM, PhD 1 Ali Rassouli, DVM, PhD 2 Behnam Meshki, DVM, PhD 1 Gholam Reza Shams, BSc
More informationTDM. Measurement techniques used to determine cyclosporine level include:
TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.
More informationGuideline for Bioequivalence Studies of Generic Products
English translation of Attachment 1 of Division-tification 0229. 10 of the Pharmaceutical and Food Safety Bureau, dated February 29, 2012 Guideline for Bioequivalence Studies of Generic Products Index
More information2- Minimum toxic concentration (MTC): The drug concentration needed to just produce a toxic effect.
BIOPHARMACEUTICS Drug Product Performance Parameters: 1- Minimum effective concentration (MEC): The minimum concentration of drug needed at the receptors to produce the desired pharmacologic effect. 2-
More informationMotor Fluctuations in Parkinson s Disease
Motor Fluctuations in Parkinson s Disease Saeed Bohlega, MD, FRCPC Senior Distinguished Consultant Department of Neurosciences King Faisal Specialist Hospital & Research Centre Outline Type of fluctuations
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: CR004357 Title of Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 mg eq. of Paliperidone Palmitate in Subjects With
More informationNoncompartmental Analysis (NCA) in PK, PK-based Design
Noncompartmental Analysis (NCA) in PK, PK-based Design Helmut Schütz BEBAC Bioequivalence and Bioavailability, Pre-Conference Workshop Ljubljana, 17 May 21 1 54 Bioequivalence History Surrogate of clinical
More informationSingle dose pharmacokinetic study of clobazam in normal
Br. J. clin. Pharmac. (1984), 18, 873-877 Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients S. JAWAD & A.. RICHS Department of Pharmacology and Therapeutics, Welsh
More informationRe-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.
Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed
More information1. Immediate 2. Delayed 3. Cumulative
1 Pharmacodynamic Principles and the Time Course of Delayed Drug Effects Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand The time course of drug action combines
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPharmacokinetics of propofol when given by intravenous
Br. J. clin. Pharmac. (199), 3, 144-148 Pharmacokinetics of propofol when given by intravenous infusion DENIS J. MORGAN', GWEN A. CAMPBELL2,* & DAVID P. CRANKSHAW2 'Victorian College of Pharmacy, 381 Royal
More informationNIH Public Access Author Manuscript Res Commun Chem Pathol Pharmacol. Author manuscript; available in PMC 2010 October 18.
NIH Public Access Author Manuscript Published in final edited form as: Res Commun Chem Pathol Pharmacol. 1986 July ; 53(1): 137 140. EFFECT OF BILE ON CYCLOSPORINE ABSORPTION IN DOGS Raman Venkataramanan
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDr. M.Mothilal Assistant professor
Dr. M.Mothilal Assistant professor Bioavailability is a measurement of the rate and extent of drug that reaches the systemic circulation from a drug product or a dosage form. There are two different types
More informationThe oral meal or oral glucose tolerance test. Original Article Two-Hour Seven-Sample Oral Glucose Tolerance Test and Meal Protocol
Original Article Two-Hour Seven-Sample Oral Glucose Tolerance Test and Meal Protocol Minimal Model Assessment of -Cell Responsivity and Insulin Sensitivity in Nondiabetic Individuals Chiara Dalla Man,
More informationEvaluation of a Scenario in Which Estimates of Bioequivalence Are Biased and a Proposed Solution: t last (Common)
Drug Development Evaluation of a Scenario in Which Estimates of Bioequivalence Are Biased and a Proposed Solution: t last (Common) The Journal of Clinical Pharmacology 2016, 56(7) 794 800 C 2015, The Authors.
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion Cabergoline Sandoz (cabergoline) SE/H/899/01-03/DC This module reflects the scientific discussion for the approval of Cabergoline Sandoz. The procedure was
More informationGastrointestinal side effects after intravenous erythromycin
Br. J. clin. Pharmac. (1986), 21, 295-299 Gastrointestinal side effects after intravenous erythromycin lactobionate K. M. DOWNEY & D. M. CHAPUT DE SAINTONGE Department of Pharmacology and Therapeutics,
More informationPharmacokinetic overview of Ortho Evra /Evra
FERTILITY AND STERILITY VOL. 77, NO. 2, SUPPL 2 FEBRUARY 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Pharmacokinetic
More informationAPDW 2016 Poster No. a90312
APDW 2016 Poster No. a90312 SYN-010, a Proprietary Modified-Release Formulation of Lovastatin Lactone, Lowered Breath Methane and Improved Stool Frequency in Patients with IBS-C Results of a multi-center,
More informationDrug Absorption and Bioavailability
Drug Absorption and Bioavailability Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 4, 2012 Office of Clinical Research Training and Medical Education National Institutes
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More informationAn evaluation of different doses of soluble aspirin and aspirin tablets in postoperative dental pain
Br. J. clin. Pharmac. (1988), 26, 463-468 An evaluation of different doses of soluble aspirin and aspirin tablets in postoperative dental pain I. S. HOLLAND', R. A. SEYMOUR2, R. P. WARD-BOOTH', R. A. ORD',
More informationAROMASIN 25mg (Tablets)
APPROVED PACKAGE INSERT AROMASIN SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: AROMASIN 25mg (Tablets) COMPOSITION: Each sugar-coated tablet contains 25 mg exemestane. Preservative: methyl p-hydroxybenzoate
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More information